Who is sponsoring NCT04028570?

NCT04028570 is sponsored by University Health Network, Toronto.

What drugs are being tested in NCT04028570?

Interventions in NCT04028570: Varying Doses of Background and Boost RT.

What condition does NCT04028570 study?

NCT04028570 studies Mesothelioma; Lung.

Is NCT04028570 still recruiting?

NCT04028570 is currently active, enrolled. Last updated 3 March 2026.

Last reviewed 2026-03-03 · How we verify

NCT04028570: SMARTER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural Resection

Active, enrolled NA Last updated 3 March 2026

What this trial tests

NA trial testing Varying Doses of Background and Boost RT in Mesothelioma; Lung in 15 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

5 September 2019

Primary endpoint
1 April 2027

1 April 2027

Quick facts

Lead sponsor	University Health Network, Toronto
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	5 September 2019
Primary completion	1 April 2027
Estimated completion	1 April 2027
Sites	1 location across Canada

Drugs / interventions tested

Varying Doses of Background and Boost RT

Conditions studied

Mesothelioma; Lung — all drugs for Mesothelioma; Lung →

Sponsor

University Health Network, Toronto

Who can join

18 and older, any sex, with Mesothelioma; Lung. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Maximum Tolerated Dose for Background Radiation
Time frame: Up to five years
AEs will be graded by CTCAE. Maximum tolerated dose is the dose level that do not result in fatal lung injury (grade 5 lung toxicity) or life-threatening or fatal treatment related toxicity (grade 4+).

Sponsor's own description

This study aims to find the maximum tolerated dose level for malignant pleural mesothelioma patients receiving background radiation + boost radiation, and surgery. Boost radiation is an experimental form of radiation that involves targeting non-uniform high doses of radiation to bulky pleural masses. We hypothesize the immunologic abscopal effect is an important component in controlling disease, and may be stimulated with highly hypofractionated doses. Doses will increase with every three patients who will be enrolled in the study until the background radiation reaches 1800 cGy or the maximum tolerated dose, whichever is lower.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Malignant mesothelioma tumours: molecular pathogenesis, diagnosis, and therapies accompanying clinical studies.
Sahu RK, Ruhi S, Jeppu AK, Al-Goshae HA, et al · · 2023 · cited 21× · PMID 37469419 · DOI 10.3389/fonc.2023.1204722
Contemporary issues in the surgical management of pleural mesothelioma.
Paajanen J, Jaklitsch MT, Bueno R. · · 2023 · cited 5× · PMID 36630097 · DOI 10.1002/jso.27152
Perioperative Treatments in Pleural Mesothelioma: State of the Art and Future Directions.
Cecchi LG, Aliprandi M, De Vincenzo F, Perrino M, et al · · 2025 · cited 3× · PMID 41097726 · DOI 10.3390/cancers17193199
Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience.
Breen WG, Garces YI, Olivier KR, Park SS, et al · · 2020 · cited 1× · PMID 32266156 · DOI 10.3389/fonc.2020.00392

Verify or expand the search:

Other recruiting trials for Mesothelioma; Lung

Currently open trials in the same condition.

NCT07126509 — Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma · NA · recruiting
NCT06581549 — Immune Microenvironment and Gene Expression Profiling in Mesothelioma · recruiting
NCT04300244 — Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma · Phase 2 · active not recruiting

Other University Health Network, Toronto trials

Trials by the same sponsor.

NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04028570 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
Last refreshed: 3 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04028570.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing